Premium
Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi‐centers with 185 patients
Author(s) -
KomatsuTanaka Mio,
Iwakiri Ryuichi,
Fujimoto Kazuma,
Fujiwara Yasuhiro,
Inamori Masahiko,
Tanaka Junji,
Shimatani Tomohiko,
Akiyama Junichi,
Ando Takashi,
Manabe Noriaki,
Kinjo Fukunori,
Deguchi Ryuzo,
Kusano Motoyasu
Publication year - 2012
Publication title -
digestive endoscopy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.5
H-Index - 56
eISSN - 1443-1661
pISSN - 0915-5635
DOI - 10.1111/j.1443-1661.2012.01301.x
Subject(s) - medicine , rabeprazole , reflux , gastroenterology , reflux esophagitis , disease , esophagitis , quality of life (healthcare) , proton pump inhibitor , nursing
Aim: The main aim of this study was to determine whether questionnaire evaluations of clinical symptoms in gastroesophageal reflux disease were useful to assess proton pump inhibitor therapy. Methods: A total of 185 Japanese patients (men, 88; women, 97; age: 55.7 ± 16.1 years) with gastroesophageal reflux disease were enrolled. The patients were divided based on the frequency scale for symptoms of gastroesophageal reflux disease: severe symptoms with scores ≥8 and mild symptoms with scores ≤7. Quality of life was evaluated with the Medical Outcomes Study 8‐Item Short‐Form Health Survey. All patients were treated with a proton pump inhibitor, rabeprazole (10 mg/day), for 8 weeks. Results: Patients were classified into four groups: reflux esophagitis with severe symptoms ( n = 92, 49.7%); reflux esophagitis with mild symptoms ( n = 17, 9.2%); non‐erosive reflux disease with severe symptoms ( n = 66, 35.7%); and non‐erosive reflux disease with mild symptoms ( n = 10, 5.4%). The dysmotility score was high in non‐erosive reflux disease with severe symptoms compared with reflux esophagitis with severe symptoms (9.1 ± 0.5 vs 6.8 ± 0.5, P < 0.05). The symptom score and quality of life in the severe symptoms groups for both reflux esophagitis and non‐erosive reflux disease were significantly improved by rabeprazole treatment. Only the reflux score was improved by rabeprazole in the reflux esophagitis with mild symptoms group; no therapeutic effect was observed for the non‐erosive reflux disease with mild symptoms group. Conclusions: Low scores on the frequency scale for the symptoms of gastroesophageal reflux disease indicate poor responsiveness to proton pump inhibitor treatment, and high scores indicate good responsiveness.